The Latest
COUR Pharmaceuticals Secures FDA Clearance of IND Application for CNP-103 in Type 1 Diabetes
Skip to primary navigation
Skip to main content
Skip to footer
COUR Pharmaceuticals
Our Company
Leadership
Board of Directors
Advisors
Partners
Contact
Our Technology
Pipeline
Our Clinical Trials
CNP-106 Myasthenia Gravis
Publications & Media
Press Releases
Publications
Careers
Tim Walbert
Former Chairman, President and Chief Executive Officer, Horizon Therapeutics;
Sr. Advisor, Amgen
